209 related articles for article (PubMed ID: 38172737)
1. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract][Full Text] [Related]
2. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract][Full Text] [Related]
4. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
[TBL] [Abstract][Full Text] [Related]
5. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression.
Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
Immunogenetics; 2023 Apr; 75(2):133-143. PubMed ID: 36515717
[TBL] [Abstract][Full Text] [Related]
6. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients.
Xu X; Wang Y; Hu X; Zhu Y; Wang J; Guo J
Neoplasia; 2023 Sep; 43():100919. PubMed ID: 37517099
[TBL] [Abstract][Full Text] [Related]
7. Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression.
Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
Cancer Res Treat; 2023 Oct; 55(4):1321-1336. PubMed ID: 37024096
[TBL] [Abstract][Full Text] [Related]
8. Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Urol Oncol; 2023 Jan; 41(1):51.e13-51.e23. PubMed ID: 36328922
[TBL] [Abstract][Full Text] [Related]
9. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Xu X; Lin J; Wang J; Wang Y; Zhu Y; Wang J; Guo J
Hum Vaccin Immunother; 2024 Dec; 20(1):2350101. PubMed ID: 38738709
[TBL] [Abstract][Full Text] [Related]
10. Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.
Wang J; Lin J; Wang J; Wang Y; Zhu Y; Xu X; Guo J
Discov Oncol; 2024 Mar; 15(1):86. PubMed ID: 38519766
[TBL] [Abstract][Full Text] [Related]
11. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
Fitzgerald KN; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Aggen DH; Carlo MI; Shah NJ; Voss MH; Feldman DR; Motzer RJ; Lee CH
Eur Urol; 2023 Mar; 83(3):195-199. PubMed ID: 36344318
[TBL] [Abstract][Full Text] [Related]
12. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
[TBL] [Abstract][Full Text] [Related]
13. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
Target Oncol; 2023 Jan; 18(1):159-168. PubMed ID: 36571708
[TBL] [Abstract][Full Text] [Related]
15. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
Esterberg E; Iyer S; Nagar SP; Davis KL; Tannir NM
Clin Genitourin Cancer; 2024 Apr; 22(2):115-125.e3. PubMed ID: 37914609
[TBL] [Abstract][Full Text] [Related]
16. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
[TBL] [Abstract][Full Text] [Related]
18. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.
Bolek H; Yekedüz E; Ürün Y
Cancer Treat Rev; 2024 Jan; 122():102667. PubMed ID: 38101099
[TBL] [Abstract][Full Text] [Related]
19. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C
Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357
[TBL] [Abstract][Full Text] [Related]
20. Real world data on IO-based therapy for metastatic renal cell carcinoma.
Stühler V; Herrmann L; Rausch S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3249-3258. PubMed ID: 35907009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
